Climb Bio annual r&d spending
2020
2021
2022
2023
2024
2025
Climb Bio R&D Spending Growth & History (CLYM)
Climb Bio's r&d spending was $46.7M for fiscal 2025.
View full Climb Bio company overviewClimb Bio annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $46.7M | $32.4M | +225.84% |
| 2024 | 2024-12-31 | $14.3M | −$1.1M | −6.98% |
| 2023 | 2023-12-31 | $15.4M | −$10.8M | −41.21% |
| 2022 | 2022-12-31 | $26.2M | $2.9M | +12.40% |
| 2021 | 2021-12-31 | $23.3M | $14.6M | +165.96% |
| 2020 | 2020-12-31 | $8.8M | — | — |
Climb Bio quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $9.7M | $3.1M | +47.74% |
| Q1 2026 | 2026-03-31 | $9.4M | −$8.0M | −45.91% |
| Q4 2025 | 2025-12-31 | $13.7M | $7.8M | +130.54% |
| Q3 2025 | 2025-09-30 | $9.1M | $2.8M | +45.40% |
| Q2 2025 | 2025-06-30 | $6.6M | $5.5M | +528.59% |
| Q1 2025 | 2025-03-31 | $17.3M | $16.2M | +1488.18% |
| Q4 2024 | 2024-12-31 | $6.0M | $2.8M | +90.57% |
| Q3 2024 | 2024-09-30 | $6.2M | $3.4M | +116.97% |
| Q2 2024 | 2024-06-30 | $1.0M | −$2.6M | −71.64% |
| Q1 2024 | 2024-03-31 | $1.1M | −$4.6M | −80.93% |
| Q4 2023 | 2023-12-31 | $3.1M | −$1.8M | −36.53% |
| Q3 2023 | 2023-09-30 | $2.9M | −$1.4M | −32.46% |
| Q2 2023 | 2023-06-30 | $3.7M | −$5.1M | −57.94% |
| Q1 2023 | 2023-03-31 | $5.7M | −$2.5M | −30.75% |
| Q4 2022 | 2022-12-31 | $4.9M | −$2.7M | −35.02% |
| Q3 2022 | 2022-09-30 | $4.3M | −$1.7M | −28.90% |
| Q2 2022 | 2022-06-30 | $8.8M | $3.3M | +60.08% |
| Q1 2022 | 2022-03-31 | $8.3M | $4.0M | +93.31% |
| Q4 2021 | 2021-12-31 | $7.6M | — | — |
| Q3 2021 | 2021-09-30 | $6.0M | $4.1M | +210.31% |
| Q2 2021 | 2021-06-30 | $5.5M | $4.2M | +313.43% |
| Q1 2021 | 2021-03-31 | $4.3M | — | — |
| Q3 2020 | 2020-09-30 | $1.9M | — | — |
| Q2 2020 | 2020-06-30 | $1.3M | — | — |
Climb Bio r&d spending trends
Over the last five fiscal years, Climb Bio's r&d spending increased from $8.8M to $46.7M, a change of $37.9M. The latest reported quarter, Q2 2026, shows $9.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Climb Bio source filings ↗